ProtAffin AG Granted Patent in EU for Lead Anti-inflammatory Product PA401

28-Jan-2009 - Austria

ProtAffin AG announced that it has been granted a patent by the European Patent Office on anti-inflammatory variants of chemokine IL-8, including the Company’s lead product PA401. PA401 is an IL-8 variant in pre-clinical development at ProtAffin to prevent inflammation in a number of chronic and acute inflammatory settings.

Whereas wild-type chemokines are over-expressed in many chronic and acute inflammatory diseases, ProtAffin has developed anti-inflammatory variants of IL-8 with increased affinity for heparin-like glycan structures found on inflamed endothelium. These anti-inflammatory products do not activate chemokine receptors found on leukocytes.

Dr. Jason Slingsby, CEO of ProtAffin commented: “We are very pleased that the European Patent Office has granted us claims protecting our lead anti-inflammatory product PA401, as well as other anti-inflammatory variants of IL-8. This is an important commercial step for us as we seek to develop and commercialise PA401 for a number of chronic and acute diseases in the world’s major pharmaceutical markets. PA401 represents a novel class of biological product which disrupts protein-glycan interactions which drive inflammation in a number of diseases with serious unmet medical need.”

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances